Description: Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.
Home Page: www.oscotec.com
A Building, Korea Bio Park
Seongnam-si,
13488
South Korea
Phone:
82 3 1628 7666
Officers
| Name | Title |
|---|---|
| Sung-Hee Son | Exec. Officer |
| Se-Nyun Kim | Exec. Officer |
| Hirose Dakashi | Exec. Officer |
| Su-Sung Lee | Exec. Officer |
| So-Jin Ahn | Exec. Officer |
| Ju-Won Kim | Exec. Officer |
| Jae-Sang Lee | Exec. Officer |
| Sung-Ho Park | Exec. Officer |
| Seung-Chul Lee | Exec. Officer |
| Mr. Jeung-Keun Kim | Chief Exec. Officer |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 18.5373 |
| IPO Date: | 2007-01-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |